Development of a panel of autoantibody against NSG1 with CEA, CYFRA21-1, and SCC-Ag for the diagnosis of esophageal squamous cell carcinoma

Zheng, Qingzhu; Zhang, Liangming; Tu, Min; Yin, Xiaoxing; Cai, Liangchun; Zhang, Songgao; Yu, Lili; Pan, Xiaojie; Huang, Yi

doi:10.1016/j.cca.2021.06.013

Cited by 21 publications

(12 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the absence of specific symptoms and lack of effective curable methods, ESCC is one of the most deadly cancers worldwide. ESCC screening mainly depends on endoscopy and tumor markers such as SCC, CEA and CA19-9 [ 8 , 10 ]. However, invasiveness and inconvenience of the endoscopy and low sensitivity and specificity of tumor markers limited the detection of ESCC at early stage.…”

Section: Discussionmentioning

confidence: 99%

“…However, due to the invasive, inconvenient, time-consuming process, and low cost-effective for individuals aged <55 years, endoscopy is not suitable for large-scale screening [ 7 , 8 ]. Although tumor markers such as squamous cell carcinoma antigen (SCC), carcinoembryonic antigen (CEA), and carbohydrate antigen 19-9 (CA19-9) are correlated with esophageal carcinogenesis, the sensitivity is less than 42% [ 9 , 10 ]. Thus, there is an urgent demand for a less invasive, convenient, and widely available method for ESCC screening.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer

Lu,

Wu,

et al. 2023

Cell Death Dis

View full text Add to dashboard Cite

Esophageal cancer is a highly incidence and deadly disease with a poor prognosis, especially in developing countries. Owing to the lack of specific symptoms and early diagnostic biomarkers, most patients are diagnosed with advanced disease, leading to a 5-year survival rate of less than 15%. Early (n = 50) and middle-advanced (n = 50) esophageal squamous cell carcinoma (ESCC) patients, as well as 71 healthy individuals, underwent 5-hydroxymethylcytosine (5hmC) sequencing on their plasma cell-free DNA (cfDNA). A Northern Chinese cohort of cfDNA 5hmC dataset of 150 ESCC patients and 183 healthy individuals were downloaded for validation. A diagnostic model was developed using cfDNA 5hmC signatures and then improved by low-pass whole genome sequencing (WGS) features of cfDNA. Conserved cfDNA 5hmC modification motifs were observed in the two independent ESCC cohorts. The diagnostic model with 5hmC features achieved an AUC of 0.810 and 0.862 in the Southern and Northern cohorts, respectively, with sensitivities of 69.3–74.3% and specificities of 82.4–90.7%. The performance was well maintained in Stage I to Stage IV, with accuracy of 70–100%, but low in Stage 0, 33.3%. Low-pass WGS of cfDNA improved the AUC to 0.934 with a sensitivity of 82.4%, a specificity of 88.2%, and an accuracy of 84.3%, particularly significantly in Stage 0, with an accuracy up to 80%. 5hmC and WGS could efficiently differentiate very early ESCC from healthy individuals. These findings imply a non-invasive and convenient method for ESCC detection when clinical treatments are available and may eventually prolong survival.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer

Lu,

Wu,

et al. 2023

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…Tumor-related factors are important indicators to evaluate the curative effect of clinical treatment for malignant tumors. As a glycoprotein, CEA is mostly found on the surface of tumor cells and can participate in cell deterioration, proliferation, and metastasis by damaging epithelial tissues and improving the adhesion ability of tumor cells [ 26 ]. SCC is a specific antigen generated during the proliferation of squamous cell carcinoma, which has high specificity and sensitivity to squamous cell carcinoma and can be used for the diagnosis and prognosis evaluation of squamous cell carcinoma [ 27 ].…”

Section: Discussionmentioning

confidence: 99%

Study on the Application Value of Concurrent Chemoradiotherapy and Clinical Nursing Pathway for Postoperative Patients with Esophageal Cancer

Yang

Zhang

Yang

et al. 2022

Journal of Oncology

View full text Add to dashboard Cite

Backgrounds To observe the value of concurrent chemoradiotherapy and clinical nursing pathway for postoperative patients with esophageal cancer (EC). Methods A total of 88 postoperative EC patients were divided into the radiotherapy group (RG group, 44 cases) and the chemoradiotherapy group (CRG group, 44 cases). The RG group received single three-dimensional conformal radiotherapy+clinical nursing pathway, and the CRG group was combined with chemotherapy on this basis. The 5-year overall survival rate, progression-free survival rate, pathological remission and survival rate, lymph node metastasis and survival rate, quality of life analysis, tumor-related factor level, and incidence of adverse reactions were compared between the two groups. Results The overall survival rates at 1, 3, and 5 years were 93.18%, 56.82%, and 50.0% in the CRG group and 86.36%, 52.27%, and 43.18% in the RG group, respectively. The 5-year progression-free survival rate of the CRG group was 60.87%, which was clearly higher than that of the RG group (33.33%). The 1-, 3-, and 5-year overall survival rates of pCR and NpCR patients were 90.48%, 80.95%, and 61.90% and 89.55%, 44.78%, and 38.81%, respectively. The overall 1-year, 3-year, and 5-year survival rates were 81.08%, 37.84, and 24.32% and 96.08%, 66.67%, and 62.75% in patients with lymph node metastasis and nonlymph node metastasis, respectively, with statistical significant differences. The emotional function, physical function, cough, pain, and eating difficulty in the CRG group were better than those in the RG group. After treatment, serum CEA, SCC, CYFRA21-1, and CA199 levels in the CRG group were obviously downregulated compared with those in the RG group. There was no obvious difference in the incidence of adverse reactions between the CRG group and the RG group. Conclusion Single radiotherapy and concurrent chemoradiotherapy can be used as effective means in the treatment of EC. Moreover, the quality of life and survival time of the concurrent chemoradiotherapy group were dramatically better than those of the single radiotherapy group, and the antitumor ability of the concurrent chemoradiotherapy group was stronger.

show abstract

“…However, due to the lack of obvious early clinical symptoms and diagnostic reliable biomarkers for ESCC, many patients are still unable to obtain prompt therapy. According to numerous studies, protein biomarkers including carcino embryonic antigen (CEA), cytokeratin 19 fragment 21-1 (CYFRA21-1), and squa mous cell carcinoma antigen (SCC-Ag) can help diagnose ESCC, but they are insufficiently sensitive and specific to offer a meaningful diagnosis for ESCC [ 20 , 21 ]; therefore, new reliable biomarkers for ESCC are still needed.…”

Section: Discussionmentioning

confidence: 99%

Anti-CXCL8 Autoantibody: A Potential Diagnostic Biomarker for Esophageal Squamous Cell Carcinoma

et al. 2022

View full text Add to dashboard Cite

Background and Objectives: Esophageal squamous cell carcinoma (ESCC) is one of the most common malignancies. Anti-tumor associated antigen autoantibodies (TAAbs) can be used as biomarkers for tumor detection. The aim of this study was to identify a reliable TAAb as the diagnostic marker for ESCC. Materials and Methods: The Cancer Genome Atlas (TCGA) database was used to screen candidate genes. The mRNA expression of the key gene was then verified by micro array dataset GSE44021 from the Gene Expression Omnibus (GEO) database and the diag nostic value of the corresponding autoantibody to the key gene in ESCC was detected by enzyme-linked im muno sorbent assay (ELISA). Results: CXCL8 was identified as the key gene. The dataset GSE44021 showed that CXCL8 mRNA expression was prominently over-expressed in ESCC tissues compared with normal tissues. ELISA results showed that the level of anti-CXCL8 autoantibody in ESCC patients was significantly higher than in normal controls and the receiver operating char ac teristic (ROC) curve indicated that anti-CXCL8 autoantibody could discriminate ESCC patients from normal controls, with the area under the ROC curve (AUC) for the verification cohort, and the validation cohort were 0.713 and 0.751, respectively. Conclusions: Our study illustrated that anti-CXCL8 autoantibody had good diagnostic value, and may become a candidate biomarker for ESCC.

show abstract

Development of a panel of autoantibody against NSG1 with CEA, CYFRA21-1, and SCC-Ag for the diagnosis of esophageal squamous cell carcinoma

Cited by 21 publications

References 20 publications

Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer

Plasma cell-free DNA 5-hydroxymethylcytosine and whole-genome sequencing signatures for early detection of esophageal cancer

Study on the Application Value of Concurrent Chemoradiotherapy and Clinical Nursing Pathway for Postoperative Patients with Esophageal Cancer

Anti-CXCL8 Autoantibody: A Potential Diagnostic Biomarker for Esophageal Squamous Cell Carcinoma

Contact Info

Product

Resources

About